Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection-Reference-Cited by-同舟云学术

Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection

Published:2021-09 Issue:S3 Volume:23 Page:40-52
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Andreasen Christine Rode¹²^ORCID,Andersen Andreas¹²^ORCID,Knop Filip Krag¹²³⁴^ORCID,Vilsbøll Tina¹²³^ORCID

Affiliation:

1. Steno Diabetes Center Copenhagen Gentofte Denmark

2. Center for Clinical Metabolic Research Gentofte Hospital, University of Copenhagen Hellerup Denmark

3. Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

4. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14500

Reference115 articles.

1. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

2. Association of Cardiometabolic Multimorbidity With Mortality

3. Heart Disease and Stroke Statistics—2021 Update

4. Relationship between glycated haemoglobin and microvascular complications: Is there a natural cut-off point for the diagnosis of diabetes?

5. Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Mild-to-Moderate Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective, Single-Arm Clinical Trial;Diabetes, Metabolic Syndrome and Obesity;2024-08

2. Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial;Frontiers in Endocrinology;2024-07-19

3. Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study;Diabetes & Metabolism Journal;2024-05-31

4. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges;World Journal of Hepatology;2024-05-27

5. Non‐insulin Parenteral Therapies;Textbook of Diabetes;2024-01-12